Whitehawk Therapeutics, Inc. (WHWK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) has a cash flow conversion efficiency ratio of -0.098x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.38 Million) by net assets ($157.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Whitehawk Therapeutics, Inc. for the company's overall valuation and market capitalisation.
Whitehawk Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Whitehawk Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Whitehawk Therapeutics, Inc. ranked by their cash flow conversion efficiency. Explore WHWK cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ABC Taiwan Electronics
TWO:3236
|
0.057x |
|
ECS ICT Bhd
KLSE:5162
|
-0.079x |
|
Mahkota Group Tbk PT
JK:MGRO
|
-0.440x |
|
SFP Tech Holdings Bhd
KLSE:0251
|
0.021x |
|
TIZIANA LIFE SCIENCES LTD
F:0RP
|
N/A |
|
Basso Industry Corp
TW:1527
|
0.014x |
|
E KOCREF CR REIT
KO:088260
|
N/A |
|
Turk Prysmian Kablo ve Sistemleri AS
IS:PRKAB
|
0.312x |
Annual Cash Flow Conversion Efficiency for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Whitehawk Therapeutics, Inc. from 2019 to 2024. View Whitehawk Therapeutics, Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-59.55 Million | -1.135x | -100.08% |
| 2023-12-31 | $105.19 Million | $-59.66 Million | -0.567x | -80.96% |
| 2022-12-31 | $158.38 Million | $-49.64 Million | -0.313x | -90.67% |
| 2021-12-31 | $136.41 Million | $-22.42 Million | -0.164x | -116.09% |
| 2020-12-31 | $-12.43 Million | $-12.70 Million | 1.022x | +22.50% |
| 2019-12-31 | $-9.09 Million | $-7.58 Million | 0.834x | -- |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more